Recombinant tissue plasminogen activator treatment for COVID-19 associated ARDS and acute cor pulmonale

Int J Infect Dis. 2021 Mar:104:108-110. doi: 10.1016/j.ijid.2020.12.043. Epub 2021 Jan 13.

Abstract

Existing literature highlights the fact that patients with COVID-19 exhibit alterations in the coagulation process and are associated with respiratory and cardiovascular diseases, including acute respiratory distress syndrome and acute cor pulmonale. In this report, we describe the effects of systemic thrombolysis on acute cor pulmonale in a patient suffering from COVID-19. We demonstrated that systemic thrombolysis successfully improved the hemodynamics of our patient and resulted in a prominent reduction in hypercapnia, alveolar dead space, and ventilatory ratio.

Keywords: ARDS; Acute cor pulmonale; COVID-19; Recombinant tissue plasminogen activator; SARS-CoV-2.

Publication types

  • Case Reports

MeSH terms

  • Acute Disease
  • Aged
  • COVID-19 / complications*
  • COVID-19 / virology
  • Heart Failure / diagnostic imaging
  • Heart Failure / drug therapy*
  • Heart Failure / etiology
  • Humans
  • Male
  • Recombinant Proteins
  • Respiratory Distress Syndrome / diagnostic imaging
  • Respiratory Distress Syndrome / drug therapy*
  • Respiratory Distress Syndrome / etiology
  • SARS-CoV-2 / physiology*
  • Thrombolytic Therapy*
  • Tissue Plasminogen Activator / therapeutic use*

Substances

  • Recombinant Proteins
  • Tissue Plasminogen Activator